Skip to main content
Premium Trial:

Request an Annual Quote

NCI To Use Thomson Reuters' Biomarker Database

NEW YORK (GenomeWeb News) - Thomson Reuters said today that the National Cancer Institute will use the company’s BiomarkerCenter database to support its research on potential cancer therapeutics.
 
Thomson Reuters said that NCI’s Developmental Therapeutics program and its associated Biomarker Program will use BiomarkerCenter, a database of information on biomarkers that alerts uses to status changes of biomarkers of interest. The company launched the database in June.
 
BiomarkerCenter, developed by Thomson Reuters subsidiary Prous Science, covers biomarkers identified in the scientific literature, patents, conferences, clinical trial information, and from other sources for various therapeutic areas such as oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders.
 
Financial terms of the agreement with NCI were not disclosed.